Sara Yousef Asha
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Sara Yousef Asha has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Zainab Lafi
Pharmacological and Diagnostic Research Center, Faculty of Pharmacy, Al-Ahliyya Amman University, Amman 19328, Jordan
4 shared publications - Maisrh Ali Alrubaye
Pharmacological and Diagnostic Research Centre, Faculty of Pharmacy, Al-Ahliyya Amman University, Amman-19328, Jordan
2 shared publications - Sina Matalqah
Pharmacological and Diagnostic Research Centre, Faculty of Pharmacy, Al-Ahliyya Amman University, Amman 19328, Jordan
2 shared publications - Alaa Sanabrah
Pharmacological and Diagnostic Research Center, Faculty of Pharmacy, Al-Ahliyya Amman University, Amman 19328, Jordan
1 shared publication - Asem N. Mhaidat
King Abdullah University Hospital, Irbid 22110, Jordan
1 shared publication - Aya Y AL Kabariti
Al-Ahliyya Amman University, Amman, Jordan
1 shared publication
Latest Publications
- Open Access
- 7 November 2026
- Published by Innovare Academic Sciences Pvt Ltd in International Journal of Applied Pharmaceutics
- p. 1-20
Enhancing Phytocompound Bioavailability Via Lipid Nanocarriers for Targeted Cancer Therapy
Despite the reported anticancer activities of phytocompounds such as curcumin, resveratrol, and quercetin, their clinical application remains limited. Therefore, since the invention of lipid-based nanoparticles (LBNPs), they were used to deliver low bioavailable bioactive compounds. Many types of lipid NPs emerged such as liposomes, solid lipid nanoparticles (SLNs), nanostructured lipid carriers (NLCs) and phytosomes. Engineered LBNPs provide controlled drug release, enhance accumulation at tumor sites through passive or active targeting mechanisms. This review discusses recent advances in LBNP delivery for phytocompounds, with emphasis on preparation methods, physicochemical characterization, and application examples. This review focuses on limitations of clinical translation, including the absence of standardized formulation procedures, inconsistent reporting of critical quality attributes, insufficient long-term safety data, manufacturing challenges, and regulatory requirements. In conclusion, LBNP toxicity and biodistribution depend on formulation characteristics, dose, biological environment, and administration route, and that active targeting may improve selectivity but does not completely eliminate off-target distribution or exposure to healthy tissues.
- 7 November 2026
- Published by Innovare Academic Sciences Pvt Ltd in International Journal of Applied Pharmaceutics
- p. 1-20
Open AccessEnhancing Phytocompound Bioavailability Via Lipid Nanocarriers for Targeted Cancer Therapy
Despite the reported anticancer activities of phytocompounds such as curcumin, resveratrol, and quercetin, their clinical application remains limited. Therefore, since the invention of lipid-based nanoparticles (LBNPs), they were used to deliver low bioavailable bioactive compounds. Many types of lipid NPs emerged such as liposomes, solid lipid nanoparticles (SLNs), nanostructured lipid carriers (NLCs) and phytosomes. Engineered LBNPs provide controlled drug release, enhance accumulation at tumor sites through passive or active targeting mechanisms. This review discusses recent advances in LBNP delivery for phytocompounds, with emphasis on preparation methods, physicochemical characterization, and application examples. This review focuses on limitations of clinical translation, including the absence of standardized formulation procedures, inconsistent reporting of critical quality attributes, insufficient long-term safety data, manufacturing challenges, and regulatory requirements. In conclusion, LBNP toxicity and biodistribution depend on formulation characteristics, dose, biological environment, and administration route, and that active targeting may improve selectivity but does not completely eliminate off-target distribution or exposure to healthy tissues.
- Open Access
Intranasal Chitosan Nano-Formulations: A Novel Frontier in Brain Cancer Therapy
Direct nose-to-brain drug delivery is emerging as a promising approach in neuro-oncology because it offers a non-invasive, needle-free route for delivering therapeutics to the brain while partially bypassing the blood–brain barrier (BBB). This approach takes advantage of the natural connections between the nasal cavity and the central nervous system, allowing drugs administered through the nose to reach brain tissues through the olfactory and trigeminal pathways. Despite its potential, successful clinical translation remains challenging because the nasal cavity presents several physiological barriers. Mucus can trap drug molecules, mucociliary clearance can rapidly remove them, and nasal enzymes can degrade them before they reach their target. Advanced nanocarrier systems are therefore being developed to overcome these barriers and improve drug transport through intracellular, paracellular, and transcellular pathways. In this context, specific structural modifications can enhance drug retention, mucus penetration, cellular uptake, and targeting efficiency. Important strategies include the use of mucoadhesive materials such as chitosan to increase residence time in the nasal cavity; hydrophilic coatings such as polyethylene glycol (PEG) to improve movement through mucus; targeting ligands to promote selective cellular uptake; and stimuli-responsive systems that respond to local conditions such as pH, redox state, or glutathione (GSH) levels. These advances are particularly relevant to the treatment of glioblastoma multiforme (GBM), one of the most aggressive and difficult-to-treat brain tumors. GBM is characterized by extensive infiltration into surrounding healthy brain tissue, making it difficult to achieve effective drug concentrations throughout both the main tumor mass and its invasive margins. Intranasally delivered chitosan-based nano-formulations may help address this problem through a series of transport steps. After administration, the nanoparticles can interact with and remain within the nasal mucosa, move across the olfactory epithelium, and pass through the cribriform plate toward the olfactory bulb. From there, they may distribute into deeper regions of the brain and potentially increase drug accumulation within both the GBM core and infiltrative tumor regions. This review presents a structured overview of engineered chitosan nano-formulations for targeted drug delivery in neuro-oncology. It focuses on their physicochemical properties, mechanisms of nose-to-brain transport, drug-loading strategies, tumor-targeting approaches, therapeutic applications, and the major challenges that must be addressed before clinical translation. Overall, these systems offer a promising strategy for improving the precision and effectiveness of drug delivery to brain tumors and may contribute to the development of more targeted treatments for GBM and other neurological malignancies.
Open AccessIntranasal Chitosan Nano-Formulations: A Novel Frontier in Brain Cancer Therapy
Direct nose-to-brain drug delivery is emerging as a promising approach in neuro-oncology because it offers a non-invasive, needle-free route for delivering therapeutics to the brain while partially bypassing the blood–brain barrier (BBB). This approach takes advantage of the natural connections between the nasal cavity and the central nervous system, allowing drugs administered through the nose to reach brain tissues through the olfactory and trigeminal pathways. Despite its potential, successful clinical translation remains challenging because the nasal cavity presents several physiological barriers. Mucus can trap drug molecules, mucociliary clearance can rapidly remove them, and nasal enzymes can degrade them before they reach their target. Advanced nanocarrier systems are therefore being developed to overcome these barriers and improve drug transport through intracellular, paracellular, and transcellular pathways. In this context, specific structural modifications can enhance drug retention, mucus penetration, cellular uptake, and targeting efficiency. Important strategies include the use of mucoadhesive materials such as chitosan to increase residence time in the nasal cavity; hydrophilic coatings such as polyethylene glycol (PEG) to improve movement through mucus; targeting ligands to promote selective cellular uptake; and stimuli-responsive systems that respond to local conditions such as pH, redox state, or glutathione (GSH) levels. These advances are particularly relevant to the treatment of glioblastoma multiforme (GBM), one of the most aggressive and difficult-to-treat brain tumors. GBM is characterized by extensive infiltration into surrounding healthy brain tissue, making it difficult to achieve effective drug concentrations throughout both the main tumor mass and its invasive margins. Intranasally delivered chitosan-based nano-formulations may help address this problem through a series of transport steps. After administration, the nanoparticles can interact with and remain within the nasal mucosa, move across the olfactory epithelium, and pass through the cribriform plate toward the olfactory bulb. From there, they may distribute into deeper regions of the brain and potentially increase drug accumulation within both the GBM core and infiltrative tumor regions. This review presents a structured overview of engineered chitosan nano-formulations for targeted drug delivery in neuro-oncology. It focuses on their physicochemical properties, mechanisms of nose-to-brain transport, drug-loading strategies, tumor-targeting approaches, therapeutic applications, and the major challenges that must be addressed before clinical translation. Overall, these systems offer a promising strategy for improving the precision and effectiveness of drug delivery to brain tumors and may contribute to the development of more targeted treatments for GBM and other neurological malignancies.
- Open Access
- 18 September 2026
- Published by MDPI AG in Pharmaceutics
- Vol. 18 (9) , 1180
Development and Characterization of a Hydrogel Incorporating Protamine–Hyaluronic Acid Nanoparticles Co-Loaded with Disulfiram and Coumarin for Diabetic Wound Healing
Background: Diabetes-associated wound healing is frequently impaired due to persistent hyperglycemia, which causes vascular dysfunction and neuropathy, thereby delaying tissue repair. Objectives: In this study, hyaluronic acid and protamine nanoparticles (HA-PRO-NPs) were developed and optimized to encapsulate disulfiram (DSF) and coumarin (COM) for potential application in diabetic wound healing. Methods: The nanoparticles were prepared using a simple ionic interaction method and characterized for their particle size, zeta potential, morphology and encapsulation efficiency. Then, HA-PRO-NPs were incorporated into a hydrogel that contains carboxymethyl cellulose (CMC) and propylene glycol (PG). The hydrogel formulations were evaluated for swelling behavior, spreadability and DSF and COM release kinetics. Results: The prepared formulations were safe against human dermal fibroblasts (HDFs), with cell viability remaining above 70% over the concentration ranges tested. In the scratch assay, HA-PROT-DSF-COM-NPs improved HDF migration, achieving approximately 81% wound closure. An in vivo study was conducted using streptozotocin-induced diabetic mice. Topical application of Gel-HA-PROT-DSF-COM-NPs promoted wound closure. The study monitored wound contraction on Days 0, 3, 7, and 12. By Day 12, topical administration of the dual-cargo system (Gel-HA-PROT-DSF-COM NPs, n = 6) achieved 78.2 ± 4.1% wound closure. This was significantly higher than the single-drug formulation (Gel-HA-PROT-DSF-NPs: 59.5 ± 4.8%) and the untreated Control (Diabetic) group (55.4 ± 5.2%, p < 0.01), while the non-diabetic Control group (non diabetic) reached 97.6 ± 3.5% closure. Semi-quantitative histopathological evaluation showed that the Gel-HA-PROT-DSF-COM NPs achieved a healing score of 4/5, characterized by optimized epidermal regeneration with preserved adnexal structures and moderate dermal remodeling. Conclusions: In conclusion, Gel-HA-PROT-DSF-COM-NPs demonstrated promising potential as a topical formulation for improving wound healing under diabetic conditions.
- 18 September 2026
- Published by MDPI AG in Pharmaceutics
- Vol. 18 (9) , 1180
Open AccessDevelopment and Characterization of a Hydrogel Incorporating Protamine–Hyaluronic Acid Nanoparticles Co-Loaded with Disulfiram and Coumarin for Diabetic Wound Healing
Background: Diabetes-associated wound healing is frequently impaired due to persistent hyperglycemia, which causes vascular dysfunction and neuropathy, thereby delaying tissue repair. Objectives: In this study, hyaluronic acid and protamine nanoparticles (HA-PRO-NPs) were developed and optimized to encapsulate disulfiram (DSF) and coumarin (COM) for potential application in diabetic wound healing. Methods: The nanoparticles were prepared using a simple ionic interaction method and characterized for their particle size, zeta potential, morphology and encapsulation efficiency. Then, HA-PRO-NPs were incorporated into a hydrogel that contains carboxymethyl cellulose (CMC) and propylene glycol (PG). The hydrogel formulations were evaluated for swelling behavior, spreadability and DSF and COM release kinetics. Results: The prepared formulations were safe against human dermal fibroblasts (HDFs), with cell viability remaining above 70% over the concentration ranges tested. In the scratch assay, HA-PROT-DSF-COM-NPs improved HDF migration, achieving approximately 81% wound closure. An in vivo study was conducted using streptozotocin-induced diabetic mice. Topical application of Gel-HA-PROT-DSF-COM-NPs promoted wound closure. The study monitored wound contraction on Days 0, 3, 7, and 12. By Day 12, topical administration of the dual-cargo system (Gel-HA-PROT-DSF-COM NPs, n = 6) achieved 78.2 ± 4.1% wound closure. This was significantly higher than the single-drug formulation (Gel-HA-PROT-DSF-NPs: 59.5 ± 4.8%) and the untreated Control (Diabetic) group (55.4 ± 5.2%, p < 0.01), while the non-diabetic Control group (non diabetic) reached 97.6 ± 3.5% closure. Semi-quantitative histopathological evaluation showed that the Gel-HA-PROT-DSF-COM NPs achieved a healing score of 4/5, characterized by optimized epidermal regeneration with preserved adnexal structures and moderate dermal remodeling. Conclusions: In conclusion, Gel-HA-PROT-DSF-COM-NPs demonstrated promising potential as a topical formulation for improving wound healing under diabetic conditions.
- Open Access
- 7 September 2025
- Published by Innovare Academic Sciences Pvt Ltd in International Journal of Applied Pharmaceutics
- p. 42-51
ADVANCED FABRICATION AND CHARACTERIZATION OF SILVER NANOPARTICLES USING AI TECHNIQUES
The integration of machine learning (ML) into nanoscience has transformed the fabrication and characterization of silver nanoparticles (AgNPs), enabling precise control over particle size, shape, and functionalization. This review highlights the application of supervised and unsupervised ML models, such as artificial neural networks (ANNs), support vector machines (SVMs), and decision trees, in optimizing AgNP synthesis parameters, including temperature, pH, and reducing agent concentration. Emphasis is placed on green synthesis methods using plant extracts, where ML predicts eco-friendly conditions with minimal experimental input. Characterization techniques benefit from ML-driven image and spectral data analysis, enhancing speed and accuracy. ML is also pivotal in predicting the toxicity and biocompatibility of AgNPs, reducing reliance on animal testing and enabling safer biomedical applications. ML reduced synthesis optimization time by 30%," and to specify the types of ML techniques applied, like neural networks or support vector machines (SVMs). Furthermore, ML enhances functionalization strategies for drug delivery, biosensing, and environmental remediation. By quantifying performance outcomes and improving reproducibility, ML supports the scalable and sustainable development of AgNPs. This review offers a detailed synthesis of current advances and identifies future opportunities for intelligent, data-driven nanomaterial design.
- 7 September 2025
- Published by Innovare Academic Sciences Pvt Ltd in International Journal of Applied Pharmaceutics
- p. 42-51
Open AccessADVANCED FABRICATION AND CHARACTERIZATION OF SILVER NANOPARTICLES USING AI TECHNIQUES
The integration of machine learning (ML) into nanoscience has transformed the fabrication and characterization of silver nanoparticles (AgNPs), enabling precise control over particle size, shape, and functionalization. This review highlights the application of supervised and unsupervised ML models, such as artificial neural networks (ANNs), support vector machines (SVMs), and decision trees, in optimizing AgNP synthesis parameters, including temperature, pH, and reducing agent concentration. Emphasis is placed on green synthesis methods using plant extracts, where ML predicts eco-friendly conditions with minimal experimental input. Characterization techniques benefit from ML-driven image and spectral data analysis, enhancing speed and accuracy. ML is also pivotal in predicting the toxicity and biocompatibility of AgNPs, reducing reliance on animal testing and enabling safer biomedical applications. ML reduced synthesis optimization time by 30%," and to specify the types of ML techniques applied, like neural networks or support vector machines (SVMs). Furthermore, ML enhances functionalization strategies for drug delivery, biosensing, and environmental remediation. By quantifying performance outcomes and improving reproducibility, ML supports the scalable and sustainable development of AgNPs. This review offers a detailed synthesis of current advances and identifies future opportunities for intelligent, data-driven nanomaterial design.